Payment overview · 2025
General Payments
$358.65
21 reported records · 11 companies
Healthcare provider profile · identity verified
Jonathan Mark Tackett, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PRESTONSBURG, KY · NPI 1922369974
Verified facts
What the public records show
CMS Open Payments records show Jonathan Mark Tackett, D.O. received $358.65 in general payments during 2025 across 21 reported records.
Novartis Pharmaceuticals Corporation accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $87.90 | 24.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $71.95 | 20.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.44 | 9.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.77 | 8.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.13 | 8.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.77 | 6.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.22 | 5.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.00 | 4.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.07 | 4.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.82 | 4.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.58 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $358.65 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $87.90 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $71.95 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $31.77 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 39 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
111 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 584 | 145 |
| Lisinopril | Lisinopril | 437 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 365 | 88 |
| Montelukast Sodium | Montelukast Sodium | 333 | 78 |
| Omeprazole | Omeprazole | 296 | 75 |
| Metformin Hcl | Metformin Hcl | 293 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 269 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 263 | 70 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 57 |
| Potassium Chloride | Potassium Chloride | 229 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 199 | 40 |
| Gabapentin | Gabapentin | 193 | 28 |
| Losartan Potassium | Losartan Potassium | 189 | 43 |
| Furosemide | Furosemide | 183 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 177 | 41 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 50 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 161 | 46 |
| Famotidine | Famotidine | 157 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 154 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 154 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 153 | 51 |
| Januvia | Sitagliptin Phosphate | 147 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 35 |
| Glipizide | Glipizide | 131 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 50 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 125 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 37 |
| Carvedilol | Carvedilol | 112 | 31 |
| Ozempic | Semaglutide | 111 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 24 |
| Prednisone | Prednisone | 102 | 82 |
| Simvastatin | Simvastatin | 102 | 27 |
| Allopurinol | Allopurinol | 100 | 25 |
| Eliquis | Apixaban | 95 | 19 |
| Trazodone Hcl | Trazodone Hcl | 95 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 91 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 17 |
| Sertraline Hcl | Sertraline Hcl | 78 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 17 |
| Bupropion Xl | Bupropion Hcl | 70 | suppressed |
| Ezetimibe | Ezetimibe | 69 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 68 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Meloxicam | Meloxicam | 60 | 18 |
| Mirtazapine | Mirtazapine | 60 | 12 |
| Ibuprofen | Ibuprofen | 53 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 50 | 42 |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | 16 |
| Jardiance | Empagliflozin | 46 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 45 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 44 | 14 |
| Linzess | Linaclotide | 42 | suppressed |
| Finasteride | Finasteride | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | suppressed |
| Kerendia | Finerenone | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Tradjenta | Linagliptin | 33 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Lansoprazole | Lansoprazole | 27 | suppressed |
| Spironolactone | Spironolactone | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 13 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Nystatin | Nystatin | 26 | 11 |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 22 | suppressed |
| Desloratadine | Desloratadine | 21 | suppressed |
| Glyburide | Glyburide | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Glimepiride | Glimepiride | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Lovastatin | Lovastatin | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $358.65 · 21 records | Novartis Pharmaceuticals Corporation | AIRSUPRA, CAPLYTA, Dexcom G6 Transmitter, EVENITY, FARXIGA, FREESTYLE LIBRE 3, Kerendia, LEQVIO, MOUNJARO, QULIPTA, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error